Dr. Hussein Assi
Claim this profileBoston Medical Center
Studies Pancreatic Neuroendocrine Tumors
Studies Tumors
6 reported clinical trials
14 drugs studied
Area of expertise
1Pancreatic Neuroendocrine Tumors
Stage IV
Stage III
2Tumors
Stage IV
HER2 negative
KRAS positive
Affiliated Hospitals
Clinical Trials Hussein Assi is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy vs Radioactive Drug
for Pancreatic Neuroendocrine Tumors
This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. The purpose of this study is to find out whether capecitabine and temozolomide or lutetium Lu 177 dotatate may kill more tumor cells in patients with advanced pancreatic neuroendocrine tumors.
Recruiting3 awards Phase 224 criteria
More about Hussein Assi
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Hussein Assi has experience with
- Nivolumab
- RYZ101
- Ipilimumab
- Carboplatin
- Paclitaxel
- Radiation Therapy
Breakdown of trials Hussein Assi has run
Pancreatic Neuroendocrine Tumors
Tumors
Neuroendocrine Tumors
Stomach Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hussein Assi specialize in?
Hussein Assi focuses on Pancreatic Neuroendocrine Tumors and Tumors. In particular, much of their work with Pancreatic Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Hussein Assi currently recruiting for clinical trials?
Yes, Hussein Assi is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Hussein Assi has studied deeply?
Yes, Hussein Assi has studied treatments such as Nivolumab, RYZ101, Ipilimumab.
What is the best way to schedule an appointment with Hussein Assi?
Apply for one of the trials that Hussein Assi is conducting.
What is the office address of Hussein Assi?
The office of Hussein Assi is located at: Boston Medical Center, Boston, Massachusetts 02118 United States. This is the address for their practice at the Boston Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.